(Lilly) May 29, 2020 - Eli Lilly and Company today announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA® (ramucirumab injection, 10 mg/mL solution), in combination with erlotinib, for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. With this approval, CYRAMZA has now received six FDA approvals to treat certain types of lung, liver, stomach and colorectal cancers.Read Article
Jack West (Posted: May 30, 2020)
This is a regimen that hasn't demonstrated a survival benefit. I would expect that it should achieve very little traction in such a crowded therapeutic landscape.